Abstracts tagged "Raynaud’s phenomenon"

Abstract Number: 0395 • ACR Convergence 2021
RNA Polymerase III Autoantibody Levels and Risk of Systemic Sclerosis in Patients with Raynaud Phenomenon
Megan Lockwood¹, Yuqing Zhang², Marcy Bolster¹, Sara Schoenfeld¹, Xiaoqing Fu¹, Seth Brownmiller¹, Ana Fernandes¹ and Flavia Castelino¹, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Quincy, MA
Background/Purpose: Raynaud phenomenon is often the initial manifestation in systemic sclerosis (SSc) and can precede other SSc symptoms by years (1). Several SSc-specific autoantibodies are…
Abstract Number: 0399 • ACR Convergence 2021
Nailfold Videocapillaroscopy Findings and Associations with Organ Involvement in Mixed Connective Tissue Disease
Camille Kasser, Gonçalo Boleto, Yannick Allanore and Jerome Avouac, Université de Paris, Service de Rhumatologie, Hôpital Cochin, AP-HP.CUP, Paris, France
Background/Purpose: Mixed connective tissue disease (MCTD) is a rare autoimmune condition characterized by Raynaud’s phenomenon, positivity of antibodies targeting the U1 small nuclear ribonucleoprotein particle…
Abstract Number: 1392 • ACR Convergence 2020
Long-Term Tolerability of Aminaphtone in Raynaud’s Phenomenon Secondary to Systemic Sclerosis
Alberto Sulli¹, Sabrina Paolino¹, Giorgia Ferrari¹, Carmen Pizzorni¹, Elvis Hysa¹, Maurizio Cutolo¹ and Emanuele Gotelli¹, ¹Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic, Genoa, Italy
Background/Purpose: Aminaphtone has been used for many years to treat microvascular disorders. In vitro Aminaphtone counteracts vasoconstriction downregulating endothelin-1 production and interferes with adhesion molecules…
Abstract Number: 1396 • ACR Convergence 2020
Digital Artery Volume Index (Davix©) Predicts Onset of Future Digital Ulcers in Patients with Systemic Sclerosis
Klodian Gjeloshi¹, Giovanni Lettieri², Fiammetta Danzo¹, Giuseppina Abignano³, Mark Hinton⁴, Anne-Maree Dean⁵, Giovanna Cuomo⁶, Olga Kubassova⁷ and Francesco Del Galdo⁵, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK and Internal Medicine Department, University of Campania Luigi Vanvitelli, Naples, Italy, Leeds, United Kingdom, ²Radiology Department, San Carlo Hospital, Potenza, Italy, Potenza, Italy, ³Rheumatology Institute of Lucania (IReL), Rheumatology Department of Lucania, San Carlo Hospital, Potenza, Italy; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK, Leeds, England, United Kingdom, ⁴IAG CEO, London, United Kingdom, London, United Kingdom, ⁵Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK, Leeds, United Kingdom, ⁶Internal Medicine Department, University of Campania Luigi Vanvitelli, Naples, Italy, Naples, Italy, ⁷Image Analysis Group, London, United Kingdom
Background/Purpose: Neointima proliferation is a key pathologic feature of Systemic Sclerosis (SSc), causing arterial vessel narrowing. It is a recognised culprit pathological lesion in Digital…
Abstract Number: 149 • 2019 ACR/ARP Annual Meeting
Teaching Rare Diseases Through Role Play: Results of an Experimental Workshop About Raynaud Phenomenon
Sébastien Sanges¹, Sandrine Morell-Dubois ², Meryem-Maud Farhat ³, Morgane Assaraf ³, Marc LAMBERT ⁴, Vincent Sobanski ³, David Launay ³ and Eric Hachulla ⁵, ¹CHRU Lille, Lille, France, ²Department of Internal Medicine and Clinical Immunology, CHU Lille, University of Lille, Lille, France, ³CHU Lille, Lille, France, ⁴Lille University Hospital, Lille, France, ⁵Dept. of Internal Medicine and Clinical Immunology, Hôpital Claude Huriez, University of Lille, Lille, France, Lille, France
Background/Purpose: Systemic autoimmune diseases are mostly taught through theoretical lectures, which do not allow for the acquisition of physical examination skills and semiologic confrontation. We…
Abstract Number: 868 • 2019 ACR/ARP Annual Meeting
The Effect of Atorvastatin on Microvascular Endothelial Function and Raynaud Phenomenon in Early Diffuse Scleroderma: Results of the “Tamer”‘ Study
Robyn Domsic¹, Maureen Laffoon ¹, Balasubramani Goundappa ², Thomas Medsger ¹, Robert Lafyatis ¹ and Steven Wisniewski ¹, ¹University of Pittsburgh, Pittsburgh, PA, ²University of Pittsburgh Epidemiology Data Center, Pittsburgh, PA
Background/Purpose: Statins have pleiotropic effects felt to influence in their beneficial cardiovascular effects. These include increased nitric oxide production and improved endothelial function, modulation of…
Abstract Number: 1635 • 2019 ACR/ARP Annual Meeting
Correlation Between Raynaud’s Condition Score, Nailfold Videocapillaroscopy and Laser Speckle Contrast Analysis in Secondary Raynaud’s Phenomenon Due to Systemic Sclerosis
Barbara Ruaro¹, Elisa Alessandri ², Massimo Ghio ³, Carmen Pizzorni ⁴, Sabrina Paolino ⁴, Andrea Casabella ⁵, Antonio De Tanti ⁶, Alberto Sulli ⁷ and Maurizio Cutolo ⁸, ¹1 Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy; 2 Cardinal Ferrari Centre, S. Stefano Rheabilitation, Fontanellato (Parma), Italy, Genoa, Italy, ²1. Research Laboratory and Academic Division of the Clinical Rheumatology Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genoa, Italy, Genoa, Italy, ³Research Laboratory and Academic Division of the Clinical Rheumatology Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genoa, Italy, Genoa, Italy, ⁴Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genoa, Italy, Genoa, Italy, ⁵1 Research Laboratory and Academic Division of the Clinical Rheumatology Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genoa, Italy, Genoa, Italy, ⁶2 Cardinal Ferrari Centre, S. Stefano Rheabilitation, Fontanellato (Parma), Italy, Fontanellato, Italy, ⁷Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Genoa, Italy, ⁸Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Genoa, Italy
Background/Purpose: To evaluate any correlation between the Raynaud's Condition Score (RCS) and the morphological and functional methods available to evaluate microvascular damage in systemic sclerosis (SSc) patients (1-4). Methods: Sixty-six…
Abstract Number: 2598 • 2019 ACR/ARP Annual Meeting
Different Treatment Backgrounds Do Not Influence Aminaphtone Efficacy in Primary and Secondary Raynaud’s Phenomenon
Alberto Sulli¹, Federica Goegan ², Emanuele Gotelli ², Massimo Patane' ³, Carmen Pizzorni ³, Sabrina Paolino ³, Elisa Alessandri ⁴ and Barbara Ruaro ⁵, ¹Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Genoa, Italy, ²Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genova, Italy., Genoa, Italy, ³Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genoa, Italy, Genoa, Italy, ⁴Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genoa, Italy, Genova, ⁵1 Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy; 2 Cardinal Ferrari Centre, S. Stefano Rheabilitation, Fontanellato (Parma), Italy, Genoa, Italy
Background/Purpose: Aminaphtone treatment improves clinical symptoms of Raynaud's phenomenon (RP) and increases peripheral blood perfusion (BP) in patients with either primary or secondary RP (1-2).The…
Abstract Number: 1730 • 2018 ACR/ARHP Annual Meeting
A Role for Duplex Ultrasound of Hand Arteries in the Assessment of the Vasculopathy Associated to Systemic Sclerosis-like Diseases
Silvia Pérez Esteban¹, Esperanza Naredo Sánchez¹, Sheila Recuero Díaz¹, Fredeswinda I. Romero-Bueno², Gabriel Herrero-Beaumont³ and Olga Sanchez-Pernaute⁴, ¹Rheumatology, Fundación Jiménez Díaz University Hospital & Health Research Institute, Madrid, Spain, ²Section for Autoimmune Diseases, Rheumatology, Fundación Jiménez Díaz University Hospital & Health Research Institute, Madrid, Spain, ³Bone and Joint Research Unit, Fundación Jiménez Díaz University Hospital & Health Research Institute, Madrid, Spain, ⁴Rheumatology Division. Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
Background/Purpose: Small vessel arteriopathy precedes the development of organ damage and tissue fibrosis in systemic sclerosis (SSc) and related disorders. It is currently considered that…
Abstract Number: 1879 • 2018 ACR/ARHP Annual Meeting
The Effects of Riociguat on Raynaud’s Phenomenon and Digital Ulcers in Patients with Diffuse Systemic Sclerosis: Results from the Phase IIb RISE-SSc Study
Dinesh Khanna¹, Yannick Allanore², Christopher P. Denton³, Masataka Kuwana⁴, Marco Matucci-Cerinic⁵, Janet E. Pope⁶, Janethe Pena⁷, Kaisa Laapas⁸, Zhen Yao⁹ and Oliver Distler¹⁰, ¹Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, ²Rheumatology A Department, Cochin Hospital, Paris Descartes University, Sorbonne Paris Cité, Paris, France, ³UCL Division of Medicine, Royal Free Campus, London, United Kingdom, ⁴Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ⁵Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ⁶Department of Medicine, University of Western Ontario, London, ON, Canada, ⁷Clinical Development, Bayer US LLC, Whippany, NJ, ⁸StatFinn Oy, Espoo, Finland, ⁹Bayer AG, Berlin, Germany, ¹⁰Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland
Background/Purpose: The soluble guanylate cyclase stimulator riociguat is approved for the treatment of pulmonary arterial hypertension associated with connective tissue disease. It was anticipated that…
Abstract Number: 2692 • 2018 ACR/ARHP Annual Meeting
High Frequency Ultrasound As a Novel Approach to Quantifying the Digital Microangiopathy of Systemic Sclerosis
Victoria Flower^1,2, Shaney Barratt^3,4, Darren Hart⁵, Amanda MacKenzie², Jacqueline Shipley⁵, Stephen Ward² and John Pauling^1,2, ¹Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Royal United Hospitals NHS Foundation Trusts, Bath, United Kingdom, ²Centre for Therapeutic Innovations & Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom, ³North Bristol NHS Trust, Bristol, United Kingdom, ⁴Academic Respiratory Unit, School of Clinical Sciences, University of Bristol, Bristol, United Kingdom, ⁵Clinical Measurement Department, Royal National Hospital for Rheumatic Diseases, Royal United Hospitals NHS Foundation Trusts, Bath, United Kingdom
Background/Purpose: Structural and functional vascular abnormalities occur in Systemic Sclerosis (SSc). We report on the use of High Frequency Ultrasound (HFUS) with Superb Microvascular Imaging…
Abstract Number: 2701 • 2018 ACR/ARHP Annual Meeting
Botulinum Toxin in the Management of Raynaud’s Phenomenon
Daniel Ennis^1,2, Zareen Ahmad³, Keshini Devakandan¹, Melanie A Anderson⁴ and Sindhu Johnson¹, ¹Toronto Scleroderma Program, Mount Sinai Hospital, Toronto Western Hospital, Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, ON, Canada, ²Rheumatology, University of British Columbia, Vancouver, BC, Canada, ³Toronto Scleroderma Program, Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁴University Health Network Library Services, Toronto General Hospital, Toronto, ON, Canada
Background/Purpose: The objectives of this study were to evaluate the effectiveness and safety of botulinum toxin injection in Raynaud’s phenomenon. Methods: Medline and Embase databases…
Abstract Number: 2889 • 2017 ACR/ARHP Annual Meeting
Aminaphtone Ameliorates Clinical Symptoms and Increases Skin Blood Perfusion in Patients with Both Primary and Secondary Raynaud Phenomenon: A Six-Month Open Study
Alberto Sulli¹, Maurizio Cutolo², Carmen Pizzorni², Sabrina Paolino², Elisa Alessandri², Emanuele Gotelli² and Barbara Ruaro², ¹Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino, Genoa, Italy, Genova, Italy, ²Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino, Genoa, Italy, Genoa, Italy
Background/Purpose: Current treatments for Raynaud's phenomenon (RP) have limited efficacy, which was mainly demonstrated by physician/patient reported outcomes. Aminaphtone is a vasoactive drug recently suggested…
Abstract Number: 745 • 2017 ACR/ARHP Annual Meeting
An International Qualitative Research Study Exploring the Patient Experience of Raynaud’s Phenomenon in Systemic Sclerosis
John D. Pauling^1,2, Robyn T. Domsic³, Lesley Ann Saketkoo⁴, Celia Almeida⁵, Tracy M. Frech⁶, Francesca Ingegnoli⁷, Jane Withey⁸, Hilary Jay⁸, Emma Dures⁹, Joanna Robson¹⁰, Neil J. McHugh^11,12, Ariane L. Herrick^13,14, Marco Matucci-Cerinic¹⁵, Dinesh Khanna¹⁶ and Sarah Hewlett¹⁷, ¹Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom, ²Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ³Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁴Tulane, New Orleans, LA, ⁵HAS - Nursing and Midwifery, University of the West of England, Bristol, United Kingdom, ⁶Division of Rheumatology, University of Utah, Salt Lake City, UT, ⁷Dept. of clinical and community science, Rheumatology, Istituto G. Pini, University of Milan, Milano, Italy, ⁸Patient Research Partner, Bath, United Kingdom, ⁹Academic Rheumatology, Bristol, University of the West of England, Bristol, Bristol, United Kingdom, ¹⁰Rheumatology, University of the West of England (UWE Bristol), Bristol, United Kingdom, ¹¹Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ¹²Department of Pharmacy and Pharmacology, The University of Bath, Bath, United Kingdom, ¹³Centre for Musculoskeletal Research, University of Manchester, MAHSC, Salford Royal Hospital, Manchester, United Kingdom, ¹⁴School of Translational Medicine, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, ¹⁵Dept of Medicine/Div of Rheum, University of Florence, Florence, Italy, ¹⁶Department of Medicine, University of Michigan Scleroderma Program, Ann Arbor, MI, ¹⁷UWE Academic Rheumatology, University of West of England, Bristol, United Kingdom
Background/Purpose: Raynaud’s phenomenon (RP) is consistently ranked highest in patient surveys exploring the frequency and impact of disease related manifestations of systemic sclerosis (SSc). SSc-RP…
Abstract Number: 1686 • 2017 ACR/ARHP Annual Meeting
Topical Nitroglycerine (NTG) Vs Matching Vehicle in Secondary Raynaud Phenomenon (RP) – a Double-Blind Crossover Study of Subjective and Physiologic Responses to Controlled Cold Challenge
Dinesh Khanna¹, Lorele Mendez², Rajaie Namas³, Mary Ellen Csuka⁴, Paul Caldron⁵, Jerry A. Molitor⁶, Alan J. Kivitz⁷, Philip Waller⁸, Lee Shapiro⁹, Sabeen Najam¹⁰, Amber Khan¹¹, Virginia D. Steen¹², Aneureka Chadha¹³ and James R Seibold¹⁴, ¹University of Michigan, Ann Arbor, MI, ²Medical Research Center of Miami, Miami, FL, ³Department of Medicine [Division of Rheumatology], University of Michigan, Ann Arbor, MI, ⁴Medicine, Medical College of Wisconsin, Milwaukee, WI, ⁵Arizona Arthritis & Rheumatology Research PLLC, Phoenix, AZ, ⁶Rheumatic & Autoimmune Diseases, University of Minnesota, Minneapolis, MN, ⁷Altoona Center for Clinical Research, Duncansville, PA, ⁸Accurate Clinical Research Inc, Houston, TX, ⁹Rheumatology, Albany Medical College, Albany, NY, ¹⁰Accurate Clinical Management LLC, Baytown, TX, ¹¹Accurate Clinical Management LLC, Houston, TX, ¹²Division of Rheumatology, Department of Medicine, MedStar Georgetown University Hospital, Washington, DC, ¹³Austin Regional Clinic, Austin, TX, ¹⁴Scleroderma Research Consultants LLC, Litchfield, CT
Background/Purpose: A topical therapy for either prevention or palliation of attacks would offer unique advantages to selected patients with Raynaud phenomenon (RP). This study used…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].